查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587591

到 2030 年基因型鑒定檢測市場預測：按產品、技術、應用、最終用戶和地區進行的全球分析

Genotyping Assay Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球基因型鑒定檢測市場規模將達到 200.9 億美元，預計到 2030 年將達到 484.4 億美元，預測期內複合年成長率為 15.8%。

基因型鑒定測定是一種分子生物學方法，用於檢查個體和生物體基因序列的差異。識別特定的遺傳標記，例如單核苷酸多態性 (SNP)、插入、缺失和拷貝數變異，以了解遺傳性狀、遺傳傾向和疾病感受性。基因型鑒定測定廣泛應用於遺傳學、藥物基因組學和個人化醫療等研究領域。

據世界衛生組織 (WHO) 稱，特異性在控制遺傳疾病方面擴大使用基因型鑒定檢測，目前超過 70% 的全基因組關聯研究 (GWAS) 都針對風險因素。 。

遺傳性疾病增加

全球遺傳疾病（包括癌症和遺傳性疾病）的增加增加了對高效診斷工具的需求。透過使用基因型鑒定測定來識別導致這些疾病的基因突變，可以進行早期診斷和早期療育。基因型鑒定對於發現可以指南治療選擇的腫瘤 DNA 突變至關重要，例如在腫瘤學中。此外，尋求疾病預防和管理策略的患者和醫療保健專業人員對基因檢測的認知不斷提高，也影響了這一趨勢。

昂貴的試劑和設備

基因型鑒定技術，尤其是次世代定序(NGS) 和微陣列分析等先進技術，需要對專用設備和試劑進行大量投資。定序平台、微陣列掃描儀和其他必要基礎設施的初始成本可能令人望而卻步，特別是對於小型實驗室和醫療設施而言。試劑和消耗品的持續支出也加劇了這種財務負擔。此外，這種高成本結構限制了資源有限環境中的獲取，從而阻礙了基因型鑒定技術在臨床診斷和研究環境中的廣泛應用。

擴大農業生物技術的應用

基因型鑒定測定在農業生物技術中的使用正在迅速擴大，提供了盈利的市場擴張機會。基因型鑒定在動物育種、作物改良以及抗病性和產量增加等理想性狀的發現的應用正在擴大。到2050年，世界人口預計將接近100億，迫切需要能夠保障糧食安全的永續農業。此外，基因型鑒定分析可以支持顯著提高農業復原力和生產力的作物（GMO）和標記輔助選擇（MAS）方法的開發。

資料解釋與管理的複雜性

基因型鑒定平台會產生大量複雜的遺傳資料，包括結構變異、拷貝數變異和單核苷酸多態性 (SNP)。由於其複雜性，處理、評估和解釋這些資料面臨許多挑戰。為了從基因組資料集集中獲得重要的見解，研究人員通常需要先進的生物資訊工具和知識。由於缺乏標準化分析流程而導致結果不一致，可能會阻礙基因型鑒定測定在臨床和研究環境中的有效使用。

COVID-19 的影響：

COVID-19 大流行為基因型鑒定檢測市場帶來了機會和挑戰。最初，大流行透過擾亂供應鏈、減少工人運轉率以及將資源轉移到與大流行相關的緊急業務來擾亂基因型鑒定實驗室的運作。然而，隨著危機的進展，對基因分型服務的需求顯著增加，特別是用於識別病毒基因突變的 COVID-19 基因分型試劑套件。由於越來越重視闡明基因突變和傾向，市場不斷擴大，刺激了該領域的技術創新和研究。這次疫情也引起了人們對個人化醫療和快速診斷重要性的關注，進一步鞏固了基因型鑒定分析在未來醫療保健規劃中的使用。

預計藥物基因體學領域在預測期內將是最大的領域。

由於對定製藥物治療的需求不斷增加以及對個人化醫療的重視，藥物基因體學領域在基因型鑒定檢測市場中佔有最大佔有率。隨著醫療保健專業人員尋求根據患者的基因圖譜確定最佳治療策略，遺傳性和危及生命的疾病數量的增加正在推動對藥物基因體學測試的需求。此外，監管機構擴大鼓勵將藥物基因組學納入藥物開發程序，也推動了該市場的成長。

診斷實驗室產業預計在預測期內複合年成長率最高。

在基因型鑒定檢測市場中，診斷實驗室領域預計將以最高的複合年成長率成長。這種成長是由基因檢測和診斷需求的不斷成長所推動的，特別是隨著醫療保健轉向更個人化的治療計劃。為了做出及時、準確的診斷，診斷實驗室對於進行基因型鑒定測定至關重要，這有助於發現與各種疾病相關的遺傳變異。此外，技術發展和高通量基因分型技術的發展提高了實驗室能力，從而增加了測試量並縮短了周轉時間。

佔比最大的地區：

由於先進的醫療系統、大量的研發支出以及 Thermo Fisher Scientific 和 Illumina 等行業巨頭的存在，北美地區佔據了基因型鑒定檢測的最大市場佔有率。北美在全球市場中佔據很大佔有率，部分原因是遺傳患者病率上升以及對個人化醫療的日益關注。該地區擁有充足的公共和私人資金用於基因組學研究，加速了尖端基因型鑒定技術的採用。

複合年成長率最高的地區：

基因型鑒定檢測市場預計將以亞太地區最高的複合年成長率成長。推動這一成長的因素包括蓬勃發展的製藥和生物製藥行業、不斷增加的研發支出以及需要尖端醫療保健解決方案的人口老化。由於衛生系統的發展和對基因檢測益處的認知不斷提高，中國和印度等國家正在引領這一擴張。此外，對生物技術和基因組學研究的大量投資正在加速基因型鑒定技術的傳播，預計亞太地區將在未來幾年成為全球基因型鑒定檢測市場的主要參與者。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球基因型鑒定檢測市場：依產品

  • 試劑和套件
  • 基因型鑒定服務
  • 裝置
    • 音序器和放大器
    • 分析儀
  • 生物資訊學
    • 軟體
    • 服務

第6章全球基因型鑒定檢測市場：依技術分類

  • 聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應
    • 數位聚合酵素鏈鎖反應
  • 微陣列
  • 定序
    • 次世代定序
    • 焦磷酸測序
    • 桑格序列
  • 毛細管電泳
    • 擴增片段長度多態性
    • 限制性內切酶片段長度多態性
    • 單鏈證實的多態性
  • 基質輔助雷射解吸/電離飛行時間法
  • 其他技術

第7章全球基因型鑒定檢測市場：依應用分類

  • 藥物基因組學
  • 診斷與個人化醫療
  • 動物遺傳學
  • 農業生物技術
  • 其他用途

第8章全球基因型鑒定檢測市場：依最終用戶分類

  • 製藥和生物製藥公司
  • 診斷實驗室
  • 學術研究所
  • 其他最終用戶

第9章全球基因型鑒定檢測市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章 公司概況

  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc
  • Danaher Corporation
  • Genewiz, Inc
  • Eurofins Scientific SE
  • Agilent Technologies, Inc
  • Roche Diagnostics Limited
  • Illumina, Inc
  • GE HealthCare
  • Promega Corporation
  • Merck KGAA
  • Integrated DNA Technologies, Inc.
  • Qiagen NV
  • Perkinelmer, Inc
Product Code: SMRC27661

According to Stratistics MRC, the Global Genotyping Assay Market is accounted for $20.09 billion in 2024 and is expected to reach $48.44 billion by 2030 growing at a CAGR of 15.8% during the forecast period. A genotyping assay is a molecular biology method that examines differences in an individual's or organisms genetic sequence. In order to comprehend inherited traits, genetic predispositions, and disease susceptibility, it identifies particular genetic markers, such as single nucleotide polymorphisms (SNPs), insertions, deletions, or copy number variations. In research domains such as genetics, pharmacogenomics, and personalized medicine, genotyping assays are extensively employed.

According to the World Health Organization (WHO), genotyping assays are increasingly being used in the global effort to control hereditary diseases, with over 70% of current genome-wide association studies (GWAS) utilizing these assays to identify risk factors and develop population-specific health strategies.

Market Dynamics:

Driver:

Growing incidence of genetic conditions

The need for efficient diagnostic tools has increased due to the rise in genetic disorders worldwide, including cancer and hereditary diseases. Early diagnosis and intervention are made possible by the identification of genetic mutations that contribute to these conditions through the use of genotyping assays. Genotyping, for instance, is essential in oncology to find tumor DNA mutations that can guide treatment choices. Additionally, this trend is also being influenced by patients' and healthcare professionals' increasing awareness of genetic testing as they look for preventative and management strategies for illnesses.

Restraint:

Expensive reagents and equipment

Investing heavily in specialized equipment and reagents is necessary for genotyping technologies, especially sophisticated techniques like next-generation sequencing (NGS) and microarray analysis. Particularly for smaller research labs and medical facilities, the upfront expenses for sequencing platforms, microarray scanners, and other required infrastructure can be unaffordable. This financial burden is also made worse by the continuous expenses of reagents and consumables. Additionally, this high cost structure prevents genotyping technologies from being widely used in clinical diagnostics and research settings due to limited access in resource-constrained settings.

Opportunity:

Expanding uses of agricultural biotechnology

Genotyping assay use in agricultural biotechnology is growing quickly, offering a profitable market expansion opportunity. The use of genotyping in animal breeding, crop improvement, and the discovery of desirable traits like disease resistance and yield enhancement is growing. Sustainable agricultural practices that can guarantee food security are desperately needed, as the world's population is expected to approach 10 billion people by 2050. Furthermore, the development of genetically modified organisms (GMOs) and marker-assisted selection (MAS) methods, which can greatly increase agricultural resilience and productivity, can be aided by genotyping assays.

Threat:

Complexity of interpreting and managing data

Large volumes of intricate genetic data, such as structural variants, copy number variations, and single nucleotide polymorphisms (SNPs), are produced by genotyping platforms. There are many difficulties in handling, evaluating, and interpreting this data because of its complexity. In order to derive significant insights from genomic datasets, researchers frequently need sophisticated bioinformatics tools and knowledge. The efficient use of genotyping assays in clinical and research contexts can be hampered by inconsistent results caused by the absence of standardized analysis pipelines.

Covid-19 Impact:

There were both opportunities and challenges for the genotyping assay market as a result of the COVID-19 pandemic. At first, the pandemic hindered genotyping lab operations by upsetting supply chains, reducing the availability of workers, and redirecting resources to urgent pandemic-related tasks. However, the demand for genotyping services increased significantly as the crisis progressed, especially for COVID-19 genotyping kits, which are used to identify the virus's genetic variations. The market grew as a result of the increased emphasis on comprehending genetic variations and predispositions, which spurred innovation and research in the area. The pandemic also brought attention to the significance of personalized medicine and quick diagnostics, which further cemented the use of genotyping assays in future medical plans.

The Pharmacogenomics segment is expected to be the largest during the forecast period

Due to the growing demand for customized drug therapies and the emphasis on personalized medicine, the pharmacogenomics segment commands the largest share of the genotyping assay market. Healthcare professionals are looking to determine the best course of treatment for patients based on their genetic profiles, which has increased demand for pharmacogenomic testing due to the rise in hereditary and life-threatening disorders. Moreover, growth in this market is also being driven by regulatory agencies' growing recommendations for the incorporation of pharmacogenomics into drug development procedures.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market for genotyping assays, the diagnostic laboratories segment is anticipated to grow at the highest CAGR. The rising need for genetic testing and diagnostics, especially as healthcare shifts to more individualized treatment plans, is what is driving this growth. In order to make timely and precise diagnoses, diagnostic labs are essential for performing genotyping assays, which help find genetic variations linked to a variety of diseases. Additionally, technological developments and the creation of high-throughput genotyping techniques are improving laboratory capabilities, enabling greater testing volumes and quicker turnaround times.

Region with largest share:

Due to its sophisticated healthcare system, substantial R&D expenditures, and the presence of industry titans like Thermo Fisher Scientific and Illumina, the North American region commands the largest market share for genotyping assays. Due in large part to the rising incidence of genetic disorders and the growing focus on personalized medicine, North America held a significant share of the global market. The adoption of cutting-edge genotyping technologies has been accelerated in the region due to strong public and private funding for genomics research.

Region with highest CAGR:

The market for genotyping assays is anticipated to grow at the highest CAGR in the Asia-Pacific region. A thriving pharmaceutical and biopharmaceutical sector, rising R&D expenditures, and an aging population that requires cutting-edge healthcare solutions are some of the factors driving this growth. Due to their developing healthcare systems and rising awareness of the advantages of genetic testing, nations like China and India are leading the way in this expansion. Moreover, it is anticipated that the region's substantial investments in biotechnology and genomics research will accelerate the uptake of genotyping technologies, positioning Asia Pacific as a major player in the global genotyping assay market in the years to come.

Key players in the market

Some of the key players in Genotyping Assay market include F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc, Danaher Corporation, Genewiz, Inc, Eurofins Scientific SE, Agilent Technologies, Inc, Roche Diagnostics Limited, Illumina, Inc, GE HealthCare, Promega Corporation, Merck KGAA, Integrated DNA Technologies, Inc., Qiagen N.V. and Perkinelmer, Inc.

Key Developments:

In April 2024, Bio-Rad Laboratories, Inc. a global leader in life science research and clinical diagnostics products, announced a collaboration agreement with Oncocyte Corporation, a precision diagnostics company, to develop and commercialize transplant monitoring products using Bio-Rad's Droplet Digital(TM) PCR (ddPCR(TM)) instruments and reagents.

In December 2023, Roche announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx's innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.

In October 2023, Thermo Fisher Scientific Inc. entered into a definitive agreement to acquire CorEvitas, a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, for $912.5 million in cash. CorEvitas will become part of Thermo Fisher's Laboratory Products and Biopharma Services segment.

Products Covered:

  • Reagents & Kits
  • Genotyping Services
  • Instruments
  • Bioinformatics

Technologies Covered:

  • Polymerase Chain Reaction
  • Microarrays
  • Sequencing
  • Capillary Electrophoresis
  • Matrix-assisted Laser Desorption/Ionization-time of Flight Mass Spectrometry
  • Other Technologies

Applications Covered:

  • Pharmacogenomics
  • Diagnostics and Personalized Medicine
  • Animal Genetics
  • Agricultural Biotechnology
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biopharmaceutical Companies
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Genotyping Assay Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents & Kits
  • 5.3 Genotyping Services
  • 5.4 Instruments
    • 5.4.1 Sequencers and Amplifiers
    • 5.4.2 Analyzers
  • 5.5 Bioinformatics
    • 5.5.1 Software
    • 5.5.2 Services

6 Global Genotyping Assay Market, By Technology

  • 6.1 Introduction
  • 6.2 Polymerase Chain Reaction
    • 6.2.1 Real-Time Polymerase Chain Reaction
    • 6.2.2 Digital Polymerase Chain Reaction
  • 6.3 Microarrays
  • 6.4 Sequencing
    • 6.4.1 Next-Generation Sequencing
    • 6.4.2 Pyrosequencing
    • 6.4.3 Sanger Sequencing
  • 6.5 Capillary Electrophoresis
    • 6.5.1 Amplified Fragment Length Polymorphism
    • 6.5.2 Restriction Fragment Length Polymorphism
    • 6.5.3 Single-Strand Confirmation Polymorphism
  • 6.6 Matrix-assisted Laser Desorption/Ionization-time of Flight Mass Spectrometry
  • 6.7 Other Technologies

7 Global Genotyping Assay Market, By Application

  • 7.1 Introduction
  • 7.2 Pharmacogenomics
  • 7.3 Diagnostics and Personalized Medicine
  • 7.4 Animal Genetics
  • 7.5 Agricultural Biotechnology
  • 7.6 Other Applications

8 Global Genotyping Assay Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical & Biopharmaceutical Companies
  • 8.3 Diagnostic Laboratories
  • 8.4 Academic & Research Institutes
  • 8.5 Other End Users

9 Global Genotyping Assay Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 F. Hoffmann-La Roche Ltd.
  • 11.2 Bio-Rad Laboratories, Inc.
  • 11.3 Thermo Fisher Scientific, Inc
  • 11.4 Danaher Corporation
  • 11.5 Genewiz, Inc
  • 11.6 Eurofins Scientific SE
  • 11.7 Agilent Technologies, Inc
  • 11.8 Roche Diagnostics Limited
  • 11.9 Illumina, Inc
  • 11.10 GE HealthCare
  • 11.11 Promega Corporation
  • 11.12 Merck KGAA
  • 11.13 Integrated DNA Technologies, Inc.
  • 11.14 Qiagen N.V.
  • 11.15 Perkinelmer, Inc

List of Tables

  • Table 1 Global Genotyping Assay Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Genotyping Assay Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Genotyping Assay Market Outlook, By Reagents & Kits (2022-2030) ($MN)
  • Table 4 Global Genotyping Assay Market Outlook, By Genotyping Services (2022-2030) ($MN)
  • Table 5 Global Genotyping Assay Market Outlook, By Instruments (2022-2030) ($MN)
  • Table 6 Global Genotyping Assay Market Outlook, By Sequencers and Amplifiers (2022-2030) ($MN)
  • Table 7 Global Genotyping Assay Market Outlook, By Analyzers (2022-2030) ($MN)
  • Table 8 Global Genotyping Assay Market Outlook, By Bioinformatics (2022-2030) ($MN)
  • Table 9 Global Genotyping Assay Market Outlook, By Software (2022-2030) ($MN)
  • Table 10 Global Genotyping Assay Market Outlook, By Services (2022-2030) ($MN)
  • Table 11 Global Genotyping Assay Market Outlook, By Technology (2022-2030) ($MN)
  • Table 12 Global Genotyping Assay Market Outlook, By Polymerase Chain Reaction (2022-2030) ($MN)
  • Table 13 Global Genotyping Assay Market Outlook, By Real-Time Polymerase Chain Reaction (2022-2030) ($MN)
  • Table 14 Global Genotyping Assay Market Outlook, By Digital Polymerase Chain Reaction (2022-2030) ($MN)
  • Table 15 Global Genotyping Assay Market Outlook, By Microarrays (2022-2030) ($MN)
  • Table 16 Global Genotyping Assay Market Outlook, By Sequencing (2022-2030) ($MN)
  • Table 17 Global Genotyping Assay Market Outlook, By Next-Generation Sequencing (2022-2030) ($MN)
  • Table 18 Global Genotyping Assay Market Outlook, By Pyrosequencing (2022-2030) ($MN)
  • Table 19 Global Genotyping Assay Market Outlook, By Sanger Sequencing (2022-2030) ($MN)
  • Table 20 Global Genotyping Assay Market Outlook, By Capillary Electrophoresis (2022-2030) ($MN)
  • Table 21 Global Genotyping Assay Market Outlook, By Amplified Fragment Length Polymorphism (2022-2030) ($MN)
  • Table 22 Global Genotyping Assay Market Outlook, By Restriction Fragment Length Polymorphism (2022-2030) ($MN)
  • Table 23 Global Genotyping Assay Market Outlook, By Single-Strand Confirmation Polymorphism (2022-2030) ($MN)
  • Table 24 Global Genotyping Assay Market Outlook, By Matrix-assisted Laser Desorption/Ionization-time of Flight Mass Spectrometry (2022-2030) ($MN)
  • Table 25 Global Genotyping Assay Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 26 Global Genotyping Assay Market Outlook, By Application (2022-2030) ($MN)
  • Table 27 Global Genotyping Assay Market Outlook, By Pharmacogenomics (2022-2030) ($MN)
  • Table 28 Global Genotyping Assay Market Outlook, By Diagnostics and Personalized Medicine (2022-2030) ($MN)
  • Table 29 Global Genotyping Assay Market Outlook, By Animal Genetics (2022-2030) ($MN)
  • Table 30 Global Genotyping Assay Market Outlook, By Agricultural Biotechnology (2022-2030) ($MN)
  • Table 31 Global Genotyping Assay Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 32 Global Genotyping Assay Market Outlook, By End User (2022-2030) ($MN)
  • Table 33 Global Genotyping Assay Market Outlook, By Pharmaceutical & Biopharmaceutical Companies (2022-2030) ($MN)
  • Table 34 Global Genotyping Assay Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 35 Global Genotyping Assay Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 36 Global Genotyping Assay Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.